title: Reply by the authors.
authors.affiliation: Department of Urologic Oncology, School of Medicine, University of Colorado Denver, Aurora, CO.
authors.forename: E David
authors.initials: ED
authors.lastname: Crawford
authors.affiliation: Ferring Pharmaceuticals, Saint-Prex, Switzerland.
authors.forename: Bo-Eric
authors.initials: BE
authors.lastname: Persson
authors.affiliation: Division of Urology, University of Toronto, Ontario, Canada.
authors.forename: Laurence
authors.initials: L
authors.lastname: Klotz
mesh_terms: D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use*; D008297:Male; D009842:Oligopeptides / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy*
chemical_list: D009842:Oligopeptides; D016729:Leuprolide